Long intergenic non-protein coding RNA 1005 (LINC01005)

Long intergenic non-protein coding RNA 1005 (LINC01005) is a member of the long intergenic non-coding RNA (lincRNA) family. LincRNAs are defined as RNA molecules longer than 200 nucleotides that do not overlap protein-coding genes and generally do not encode proteins[1][3]. While numerous lincRNAs have been shown to play roles in regulating gene expression at the chromatin, transcriptional, or post-transcriptional levels, and some are implicated in disease, there are currently no published data describing the specific biological function, involvement in disease, or druggability of LINC01005 itself. Thus, LINC01005 is not currently recognized as a validated therapeutic target or biomarker. Nevertheless, as with other lincRNAs, ongoing research may clarify its potential significance in human biology or disease in the future[1][3][5]. Essential context and supporting details: - LincRNAs like LINC01005 are part of a very large RNA "dark matter" that often has poorly characterized function but can act as regulators of neighboring or distant genes, either by influencing chromatin state, acting as molecular sponges for microRNAs, or participating in transcriptional complexes[1][3][5]. - The functional annotation of lincRNAs is often gene-specific, and only a minority have been well-characterized; extensive functional screens show some lincRNAs can affect cell cycle, viability, or other phenotypes when perturbed, but LINC01005 was not among characterized cancer-associated lncRNAs or lincRNAs in the provided references[2][3]. - No drugs, clinical trials, or disease associations involving LINC01005 itself were found in available authoritative resources[1][2][3][5]. - There is nothing incorrect about the target’s designation or naming; it is a legitimate entry in human gene nomenclature, but it is not a classical pharmacological or therapeutic "target" at this time.

Other names

LINC01005

None known